09.03.26 -- CDMO Selection For Small Biotech: Amit Jain On Avoiding Costly Transfers

ADCs with similar antibody sequences can behave differently due to linker and payload choices. Analytical tools reveal structural and stability differences critical to therapeutic performance.

Here are the factors that are driving blister to the forefront of pharmaceutical packaging, and at an even faster rate than its current growth.

AI progress is stalled by fragmented, low-quality data, not technology. Standardization, automation, and cultural change transform disconnected datasets into a foundation for smarter decisions.

Stop the cycle of "click-through coma" in GXP training. Discover how scenario-based learning and role-specific curricula reduce compliance risks and drive meaningful engagement.

Explore how integrated molecular design and formulation strategies can overcome the unique oral-delivery challenges of PROTACs, transforming complex degraders into viable, scalable medicines.

Discover three tools that facilitate a successful journey from candidate compound to clinical triumph: solid form screening, PBPK modeling, and AI-enabled route scouting.

Modernize sterile manufacturing with robotic fill-finish systems. Achieve multi-format flexibility and risk reduction to meet the rigorous demands of personalized medicine and small-batch production.

Optimize NGS workflows by using digital PCR for absolute quantification. Improve library quality, reduce bias, and gain sensitive validation for rare variants in complex genomic samples.

Examine how predictive modeling, advanced material characterization, and data-driven process insights support manufacturing readiness and confident launch decisions.

Join product and application experts Anne-Grit Klees, Carine Krebs, and Esther Welterlin to uncover the benefits of using a new rapid microbial detection platform.

See how to effectively manage chemical residue buildup in cleanrooms through proper solvent selection, dwell time, and mechanical removal to support regulatory compliance.

Fast‑track, data‑driven formulation strategies align early decisions with long‑term goals, enabling First‑in‑Human progress while reducing risk and avoiding rework.

Differentiating GMP from cGMP helps facility teams design cleanrooms that meet modern contamination controls, process flows, and regulatory standards.

Gain insight into how a biopharmaceutical company can de-risk the launch process by choosing a suitable autoinjector technology and partner.

Autoinjectors add mechanical forces and interactions that change how container closure integrity must be evaluated. Learn why device complexity creates new risks and how testing strategies must adapt.

By establishing robust manufacturing processes and scalable production strategies from the outset, developers can help de-risk orphan drug production, improve efficiency, and more.